Hyalgan

Hyalgan is a prescription intra‑articular injection solution that contains sodium hyaluronate as its active ingredient. It is supplied in a sterile liquid form for injection into the knee joint and is marketed in the European Union. The product functions as a viscosupplement and clinical therapy, aiming to restore the viscoelastic properties of synovial fluid in patients with osteoarthritis. Hyalgan is classified under ATC code M02AX02.

Hyalgan is indicated for the symptomatic treatment of osteoarthritis of the knee, where it is administered as an intra‑articular injection to supplement joint lubrication.

- Reduces knee pain associated with mild to moderate osteoarthritis. - Improves joint function and range of motion in affected knees. - May delay the need for surgical interventions such as knee replacement. - Used as part of a comprehensive osteoarthritis management plan that includes physical therapy and weight control. - Administered in a series of injections, typically one injection per week for three to five weeks, under medical supervision.

Adverse reactions to Hyalgan are generally localized to the injection site, but systemic events have also been reported.

Common: - Mild pain or tenderness at the injection site. - Swelling or effusion of the knee joint. - Warmth or redness around the injection area. - Temporary stiffness or reduced range of motion.

Serious: - Acute joint inflammation (synovitis) with severe pain. - Allergic reaction presenting as rash, itching, or hives. - Infection of the joint (septic arthritis) indicated by fever and worsening pain. - Rapidly progressive osteoarthritis reported in rare cases.

Before initiating Hyalgan therapy, clinicians should evaluate patient history and joint condition to minimize risks.

- Do not use in patients with known hypersensitivity to hyaluronic acid or any component of the formulation. - Avoid intra‑articular injection in knees with active infection, septic arthritis, or skin lesions over the injection site. - Caution in patients with severe joint deformity, advanced osteoarthritis, or recent knee surgery. - Assess renal function in patients with severe renal impairment, as hyaluronate is cleared renally. - Use pregnancy and lactation only when potential benefits justify potential risks, as safety data are limited. - Monitor for signs of inflammation or infection after each injection.

Hyalgan may interact with other agents that affect joint health or systemic inflammation, and certain medications can influence injection safety.

Avoid: - Concurrent intra‑articular corticosteroid injections within the same treatment cycle. - Use of systemic anticoagulants or antiplatelet drugs without appropriate monitoring, due to increased bleeding risk at the injection site.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may mask early signs of joint inflammation. - Disease‑modifying osteoarthritis drugs (DMOADs) or other viscosupplements, as combined effects are not well studied. - Immunosuppressive therapies that could increase infection risk. - High‑dose vitamin C supplements, which may affect hyaluronate metabolism (theoretical).